Engine Biosciences Welcomes Dr. Robert Abraham as CSO to Propel Oncology Innovations
Engine Biosciences, a groundbreaking company that specializes in the development of cancer treatments through advanced machine learning and functional genomics, has announced the appointment of Dr. Robert (Bob) Abraham as its Chief Scientific Officer (CSO). This strategic move is poised to enhance the organization's already impressive capabilities in drug discovery and development, particularly in the field of precision oncology.
Dr. Abraham is a distinguished figure in the world of oncology with over thirty years of experience in scientific research and its application in therapy development. His extensive career includes significant leadership roles within both academia and the pharmaceutical industry. Dr. Abraham joins Engine at a pivotal time as the company works to bring its innovative drug candidates to clinical trials, reflecting its commitment to creating effective treatments for cancer patients.
The CEO of Engine Biosciences, Jeffrey Lu, expressed enthusiasm about Dr. Abraham's appointment, highlighting his proven history of translating complex scientific advancements into real-world therapeutic solutions. "Bob's career reflects an extraordinary track record in translating science into therapeutics and patient impact. His deep expertise in oncology drug discovery and development, and his leadership of world-class R&D organizations, are a great match for our platform and pipeline rooted in innovative science and significant clinical potential," Lu stated.
Upon his appointment, Dr. Abraham articulated his eagerness to collaborate with the talented team at Engine. He aims to leverage the company's state-of-the-art technologies in genomics and machine learning to discover new cancer dependencies and biomarkers. This strategic focus is targeted at producing meaningful medicines that are tailored to specific cancer patient populations.
Throughout his distinguished career, Dr. Abraham has been instrumental in the development of eleven FDA-approved oncology drugs. Before joining Engine, he held prominent roles, including Executive Vice President and Head of Cancer Biology at Odyssey Therapeutics and Chief Scientific Officer at Vividion Therapeutics, which was later acquired by Bayer. His tenure at Pfizer spanned a decade, during which he was Senior Vice President and led the Oncology R&D group, steering global cancer drug discovery efforts.
Dr. Abraham's academic background includes esteemed appointments at the Mayo Clinic, Duke University, and the Sanford-Burnham-Prebys Medical Discovery Institute. He is a prolific author, having published over 230 scientific papers which have received more than 59,000 citations globally. His expertise encompasses various fields, including cancer biology, immunology, and signal transduction, and he earned his PhD in Pharmacology from the University of Pittsburgh, complemented by postdoctoral training at the Mayo Clinic.
Engine Biosciences employs its proprietary NetMAPPR platform, which integrates artificial intelligence with functional genomics. This innovative approach aims to unveil key genetic interactions and specific vulnerabilities of tumors. The company has developed the largest-known knowledge database for synthetic lethality and is pursuing multiple internal and partnered programs aimed at creating first-in-class precision oncology treatments. With a strong focus on addressing unmet medical needs, Engine is highly motivated to deliver targeted solutions for patients battling cancer.
As Engine Biosciences advances its research and drug development programs, Dr. Abraham's leadership is expected to significantly contribute to its success. The company's collaborative spirit underscores its dedication to creating effective therapies, and with Dr. Abraham at the helm of scientific operations, the future of Engine biosciences looks promising as it endeavors to impact the field of oncology profoundly. For more details, visit Engine's website and follow them on LinkedIn for updates on their pathway forward in precision oncology.
Dr. Abraham is a distinguished figure in the world of oncology with over thirty years of experience in scientific research and its application in therapy development. His extensive career includes significant leadership roles within both academia and the pharmaceutical industry. Dr. Abraham joins Engine at a pivotal time as the company works to bring its innovative drug candidates to clinical trials, reflecting its commitment to creating effective treatments for cancer patients.
The CEO of Engine Biosciences, Jeffrey Lu, expressed enthusiasm about Dr. Abraham's appointment, highlighting his proven history of translating complex scientific advancements into real-world therapeutic solutions. "Bob's career reflects an extraordinary track record in translating science into therapeutics and patient impact. His deep expertise in oncology drug discovery and development, and his leadership of world-class R&D organizations, are a great match for our platform and pipeline rooted in innovative science and significant clinical potential," Lu stated.
Upon his appointment, Dr. Abraham articulated his eagerness to collaborate with the talented team at Engine. He aims to leverage the company's state-of-the-art technologies in genomics and machine learning to discover new cancer dependencies and biomarkers. This strategic focus is targeted at producing meaningful medicines that are tailored to specific cancer patient populations.
Throughout his distinguished career, Dr. Abraham has been instrumental in the development of eleven FDA-approved oncology drugs. Before joining Engine, he held prominent roles, including Executive Vice President and Head of Cancer Biology at Odyssey Therapeutics and Chief Scientific Officer at Vividion Therapeutics, which was later acquired by Bayer. His tenure at Pfizer spanned a decade, during which he was Senior Vice President and led the Oncology R&D group, steering global cancer drug discovery efforts.
Dr. Abraham's academic background includes esteemed appointments at the Mayo Clinic, Duke University, and the Sanford-Burnham-Prebys Medical Discovery Institute. He is a prolific author, having published over 230 scientific papers which have received more than 59,000 citations globally. His expertise encompasses various fields, including cancer biology, immunology, and signal transduction, and he earned his PhD in Pharmacology from the University of Pittsburgh, complemented by postdoctoral training at the Mayo Clinic.
Engine Biosciences employs its proprietary NetMAPPR platform, which integrates artificial intelligence with functional genomics. This innovative approach aims to unveil key genetic interactions and specific vulnerabilities of tumors. The company has developed the largest-known knowledge database for synthetic lethality and is pursuing multiple internal and partnered programs aimed at creating first-in-class precision oncology treatments. With a strong focus on addressing unmet medical needs, Engine is highly motivated to deliver targeted solutions for patients battling cancer.
As Engine Biosciences advances its research and drug development programs, Dr. Abraham's leadership is expected to significantly contribute to its success. The company's collaborative spirit underscores its dedication to creating effective therapies, and with Dr. Abraham at the helm of scientific operations, the future of Engine biosciences looks promising as it endeavors to impact the field of oncology profoundly. For more details, visit Engine's website and follow them on LinkedIn for updates on their pathway forward in precision oncology.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.